Clinical Trial Update: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) [Phase 3]

View source ↗

Summary

Open-label extension study PROSERA-EXT of seralutinib in adults with pulmonary arterial hypertension is ongoing in Phase 3, with the status reported as active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Seralutinib (Seralutinib)

Snippet

Sponsor: GB002, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: ACTIVE_NOT_RECRUITING